JRCT ID: jRCT1031230453
Registered date:19/11/2023
BUILD Study
Basic Information
Recruitment status | Recruiting |
---|---|
Health condition(s) or Problem(s) studied | gastric cancer, breast cancer |
Date of first enrollment | 19/11/2023 |
Target sample size | |
Countries of recruitment | |
Study type | Observational |
Intervention(s) |
Outcome(s)
Primary Outcome | Presence or absence of ILD |
---|---|
Secondary Outcome |
Key inclusion & exclusion criteria
Age minimum | Not applicable |
---|---|
Age maximum | Not applicable |
Gender | |
Include criteria | 1) Patients with breast or gastric cancer who are scheduled to start or have started their first T-DXd treatment in January 2022 or later. 2) Written consent for this study has been obtained from the patient. |
Exclude criteria | 1) Patients with a history of interstitial lung disease or undeniable on pre-enrollment testing 2) Patients participating in a clinical trial 3) Patients who are deemed inappropriate by the principal investigator or sub investigator |
Related Information
Primary Sponsor | Yasunaga Masahiro |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) |
Contact
Public contact | |
Name | Masahiro Yasunaga |
Address | 6-5-1 Kashiwanoha, Kashiwa-shi Chiba, 277-8577 Japan Chiba Japan 277-8577 |
Telephone | +81-4-7133-1111 |
mayasuna@east.ncc.go.jp | |
Affiliation | National Cancer Center Hospital East |
Scientific contact | |
Name | Masahiro Yasunaga |
Address | 6-5-1 Kashiwanoha, Kashiwa-shi Chiba, 277-8577 Japan Chiba Japan 277-8577 |
Telephone | +81-4-7133-1111 |
mayasuna@east.ncc.go.jp | |
Affiliation | National Cancer Center Hospital East |